ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.

Methadone is a mu-opioid receptor agonist used for treating opiate dependence. The range of effective methadone doses is broad. Part of the large inter-individual variability in efficacy may be accounted for by genetic factors. Methadone is a substrate of the transporter P-glycoprotein (P-gp) 170 that is encoded by the ABCB1 (MDR1) gene. Thus, P-gp variants may play a role in methadone absorption and distribution. We assessed the association between ABCB1 polymorphisms and methadone dose requirements in 98 methadone-maintained patients. The stabilizing methadone doses were normally distributed with a mean and median dose of 160 mg/day (range 30-280 mg/day). Statistical analysis showed significant difference in genotype frequencies between the 'higher' (>150 mg/day) and 'lower' (< or =150 mg/day) methadone dose groups for single nucleotide polymorphism (SNP) 1236C>T (rs1128503) (experiment-wise P = 0.0325). Furthermore, individuals bearing the 3-locus genotype pattern TT-TT-TT (rs1045642, rs2032582 and rs1128503) have an approximately 5-fold chance of requiring the 'higher' methadone dose, while individuals heterozygous for these three SNPs have an approximately 3-fold chance of stabilizing at the 'lower' methadone dose (point-wise P-value = 0.026). These data suggest that specific ABCB1 variants may have clinical relevance by influencing the methadone dose required to prevent withdrawal symptoms and relapse in this population.

[1]  C. Eap,et al.  In vitro P-Glycoprotein-Mediated Transport of (R)-, (S)-, (R,S)-Methadone, LAAM and Their Main Metabolites , 2007, Pharmacology.

[2]  G. Mann,et al.  Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype , 2007, Clinical pharmacology and therapeutics.

[3]  Jingbo Wang,et al.  Signatures of recent positive selection at the ATP-binding cassette drug transporter superfamily gene loci. , 2007, Human molecular genetics.

[4]  M. Kreek.  Introduction to Addictive Disorders: Implications for Pharmacotherapies , 2007 .

[5]  Andrew A Somogyi,et al.  Pharmacogenetics of Opioids , 2007, Clinical pharmacology and therapeutics.

[6]  M. Kreek,et al.  Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. , 2007, Addiction.

[7]  K. Dahlen,et al.  ABCB1 genetic variability and methadone dosage requirements in opioid‐dependent individuals , 2006, Clinical pharmacology and therapeutics.

[8]  S. Duan,et al.  Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. , 2006, Pharmacogenomics.

[9]  R. Ho,et al.  MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. , 2006, Journal of pharmaceutical sciences.

[10]  S. Schreiber,et al.  Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. , 2006, Drug and alcohol dependence.

[11]  R. Kerb.  Implications of genetic polymorphisms in drug transporters for pharmacotherapy. , 2006, Cancer letters.

[12]  D. Goldstein,et al.  ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. , 2006, Human molecular genetics.

[13]  R. Woosley,et al.  QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system , 2005, Pharmacoepidemiology and drug safety.

[14]  Andrew D. Johnson,et al.  Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability , 2005, Pharmacogenetics and genomics.

[15]  S. Schreiber,et al.  Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain , 2005, Pain.

[16]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[17]  A. Nagler,et al.  Genotype and Allele Frequencies of C3435T Polymorphism of the MDR1 Gene in Various Jewish Populations of Israel , 2004, Therapeutic drug monitoring.

[18]  J. Kigawa,et al.  Haplotype-Oriented Genetic Analysis and Functional Assessment of Promoter Variants in the MDR1 (ABCB1) Gene , 2004, Journal of Pharmacology and Experimental Therapeutics.

[19]  T. Sakaeda,et al.  Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. , 2004, Current topics in medicinal chemistry.

[20]  Kun Tang,et al.  Genomic evidence for recent positive selection at the human MDR1 gene locus. , 2004, Human molecular genetics.

[21]  C. L. Graff,et al.  Variable modulation of opioid brain uptake by P-glycoprotein in mice. , 2004, Biochemical pharmacology.

[22]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[23]  Chava Kimchi-Sarfaty,et al.  P-glycoprotein: from genomics to mechanism , 2003, Oncogene.

[24]  Conrad C. Huang,et al.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. , 2003, Pharmacogenetics.

[25]  M. Kreek,et al.  History and current status of opioid maintenance treatments: blending conference session. , 2002, Journal of substance abuse treatment.

[26]  Kun Tang,et al.  Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. , 2002, Pharmacogenetics.

[27]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[28]  J. Ott,et al.  Trimming, weighting, and grouping SNPs in human case-control association studies. , 2001, Genome research.

[29]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[30]  H. McLeod,et al.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.

[31]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Metzger,et al.  The Fifth Edition of the Addiction Severity Index. , 1992, Journal of substance abuse treatment.

[33]  N. Benowitz,et al.  Phenytoin-induced methadone withdrawal. , 1981, Annals of internal medicine.

[34]  J. Winchester,et al.  Clinical analgesic nephropathy. , 1981, Archives of internal medicine.

[35]  M. Kreek,et al.  Hepatic extraction of long- and short-acting narcotics in the isolated perfused rabbit liver. , 1978, Gastroenterology.

[36]  M. Kreek,et al.  DRUG INTERACTIONS WITH METHADONE * , 1976, Annals of the New York Academy of Sciences.

[37]  M. Kreek,et al.  Rifampin-induced methadone withdrawal. , 1976, The New England journal of medicine.

[38]  Kreek Mj.  Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. , 1973 .

[39]  Ji-Young Park,et al.  Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. , 2007, British journal of clinical pharmacology.

[40]  M. Gottesman,et al.  Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. , 2007, Pharmacogenomics.

[41]  D. Sibley.  Handbook of contemporary neuropharmacology , 2007 .

[42]  M. Gelkopf,et al.  Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach. , 2002, The Israel journal of psychiatry and related sciences.

[43]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[44]  M. Kreek,et al.  Availability of reliable serum methadone determination for management of symptomatic patients. , 1995, Journal of addictive diseases.

[45]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Kreek.  Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. , 1973, New York state journal of medicine.

[47]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .